You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾美疫苗(06660.HK)公開發售獲超額認購3.15倍 預計10月6日掛牌上市
格隆匯 10-05 07:04

格隆匯10月5日丨艾美疫苗(06660.HK)發佈公吿,公司全球發售971.4萬股股份,其中香港發售股份97.16萬股,國際發售股份874.24萬股,另有15%超額配股權;發售價為每股發售股份16.16港元,每手買賣單位200股;高盛、中金公司、中信建投國際及麥格理為聯席保薦人;預期股份將於2022年10月6日於聯交所主板掛牌上市。

香港公開發售項下初步提呈發售的香港發售股份已獲超額認購。根據香港公開發售合共接獲2520份有效申請,認購合共306.2萬股香港發售股份,相當於香港公開發售項下初步可供認購的H股總數約3.15倍。國際發售項下初步提呈發售的發售股份已獲超額認購,相當於國際發售項下初步可供認購國際發售股份總數的約3.27倍。

按發售價16.16港元計算,公司估計全球發售所得款項淨額約為7001萬港元(假設超額配股權未獲行使)。公司擬將所得款項淨額約4200萬港元將用於推進集團在研疫苗的研發及持續豐富集團的疫苗管線;約2450萬港元將用於為建設新生產設施的資本開支提供資金,以擴大集團新疫苗產品的產能;及約351萬港元將投入集團的銷售及營銷活動,包括擴大集團的銷售及營銷團隊,為更多學術推廣活動撥付資金及為集團的新疫苗產品開展上市前營銷活動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account